In 1977, Dr. Larry Hendry and collaborators reported that a wide variety of biologically active small molecules formed stereospecific interactions with partially unwound sites in double stranded DNA. These observations led to the discovery that degree of fit into DNA was predictive of biological activity among certain classes of molecules. Computer modeling and energy calculations provided confirmation of these initial observations resulted in the development of gene-based pharmacophores and search engines for drug development.

Using patented and proprietary in-silico processes, API has the capability to: 1) (design/optimize) molecules with a high likelihood of possessing a desired biological activity; and 2) evaluate existing or designed molecules to predict whether they possess one or more specific biological activities. Using patent-pending methods, large databases of individual molecules may be evaluated simultaneously to predict biological activity.

To date, API has employed the technology: 1) in designing novel compounds with predicted biological activity and degree of bio-activity and 2) in searching large databases of drug-like compounds for potential lead candidates of desired biological activity.

Validation has been shown in vitro and in vivo. Search results of stereo-chemically accurate databases culled with the technology show enrichment rates in desired bio-activity well above industry standard.